ResMed’s $290M Volume Surge Fails to Halt 3.12% Slide as Sleep Therapy Sector Volatility Sends It to 382nd in Trading Rank

On September 10, 2025, , . , . The decline came amid mixed signals from recent developments in the sleep therapy and respiratory care sector.

Recent reports highlighted a shift in reimbursement policies for home sleep apnea devices in key markets, creating uncertainty for providers like ResMed. Analysts noted that while the company maintains a dominant market share in CPAP technology, regulatory adjustments could pressure short-term revenue streams. Additionally, a separate industry-wide review of durable medical equipment pricing models added to sector-wide volatility.

Backtesting this strategy requires specifying key parameters to ensure accurate results. The universe typically includes all U.S. stocks listed on NYSE, NASDAQ, or NYSE-Arca since 2022. A standard approach ranks assets by prior-day volume, purchases the top 500 at the next day’s open, and exits by close. Transaction costs are often excluded unless specified. For execution, daily rebalancing with equal weighting is default, though alternative schemes can be applied. The test will generate cumulative returns and statistical summaries using historical price and volume data from January 3, 2022, to the present.